UCP2 and Stroke: The PPARα inhibitor significantly counteracted the stimulatory effect of the BO juice on UCP2 expression, therefore leading to 100% stroke occurrence by the eighth week of treatment (Figures 6a–e), consistently with previous findings.25 The SBP and BW values upon these treatments are reported in the Supplementary Table S1.